FGFR3 and ARID1A mutations may represent actionable targets in TACSTD2-high urothelial cancer, while KRAS mutations may be an attractive target for TACSTD2-high CRC and pancreatic cancer. This evidence concerns the gene ARID1A and familial pancreatic carcinoma.